From SEC EDGAR

Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update

- Management conference call at 8:30 a.m. ET today -

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…

Citius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Data featured in oral presentation at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG)…

Relay Therapeutics, Inc.

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Edgewise Therapeutics, Inc.

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING DEVELOPMENT OF SER-155 TO PREVENT IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC)

Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an…

Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion…

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

HCA Healthcare, Inc.

HCA Announces Proposed PUBLIC Offering of Senior Notes

Travere Therapeutics, Inc.

Travere Therapeutics Reports Third Quarter 2026 Financial Results

Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

- Agreement complements revenue from standard gene expression and DRP® services